Previsión
| Comprar |
1 |
| Mantener |
1 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Kazia Therapeutics announces capital raise of about $40m, shares fall
Kazia Therapeutics said it will sell 2,580,000 ADS at $15.50 each, expecting gross proceeds of around $40m before fees. In addition, series A and series B warrants are being offered, the exercise of which could generate a further roughly $80m; exercise conditions are tied to the release of clinical trial data for certain breast cancer subtypes. The funds are intended primarily to finance the clinical development of lead candidate Paxalisib and to provide working capital. The offering, accompanied by Leerink Partners, Guggenheim, BTIG and Needham, is expected to close around August 31, 2026; the ADRs fell about 6.2% in premarket trading. » Más en de.investing.com
Kazia: Paxalisib shows high response rate in metastatic triple-negative breast cancer
In an ongoing phase 1b study of Paxalisib in combination with pembrolizumab and chemotherapy, six evaluable patients with metastatic triple-negative breast cancer derived clinical benefit. Five of the six patients achieved an objective response (1 complete, 4 partial remissions; objective response rate 83%), and the remaining patient had disease stabilization; responses occurred about three months after randomization and involved, among others, lung, liver, bone, lymph node and CNS lesions. Marked median reductions in circulating tumor cell clusters (83%) and terminally exhausted T cells (51%) were observed, without serious adverse events attributed to Paxalisib. Recruitment is expected to continue until July 2027, with interim results announced for 2026 and 2027. » Más en de.investing.com
Kazia Therapeutics reports promising preclinical data on protein degrader NDL2
Kazia Therapeutics released preclinical data on NDL2, a potential first-in-class protein degrader designed to eliminate nuclear PD-L1. In triple-negative breast cancer models, NDL2 reduced tumor volume as monotherapy by 49% and in combination with anti-PD-1 by 73%, and reduced lung metastases by 50%. The program showed no observed toxicity; IND-enabling studies are ongoing and first clinical trials are planned for 2027, with additional data expected in 2026. » Más en de.investing.com
Kazia Therapeutics meets Nasdaq listing requirements again, hearing canceled
Kazia Therapeutics reports that it has again met Nasdaq listing requirements, resulting in the cancellation of the hearing scheduled for January 8, 2026. The company has now satisfied the alternative minimum requirement of $2.5 million in stockholders’ equity under Listing Rule 5550(b)(1). Its American Depositary Shares remain listed on the Nasdaq Capital Market. » Más en de.investing.com
Kazia Therapeutics secures 46.5 Mio. USD through private placement and meets Nasdaq requirement
Kazia Therapeutics raised net proceeds of approximately 46.5 million USD through a private placement. The company sold 4,530,854,000 common shares at 0.01 USD each and issued pre-funded warrants for up to 938,490 ADS at 4.9999 USD each; each ADS represents 500 common shares. Konik Capital Partners acted as placement agent and also received warrants to purchase up to 700,013 ADS at 7.50 USD, exercisable after 180 days with a five-year term. Kazia expects the transaction to result in equity above the 2.5 million USD minimum required for continued listing on the Nasdaq Capital Market and will notify the Nasdaq Hearings Panel of the restoration of compliance. » Más en de.investing.com
Datos financieros
En el último año, Kazia Therapeutics tuvo unos ingresos de 1,43 M € y un beneficio neto de -16,65 M €
| (EUR) | 2024 | YoY |
|---|---|---|
| Ingresos | 1,43 M | 423.466,03 % |
| Beneficio bruto | 1,43 M | 423.466,03 % |
| Beneficio neto | -16,65 M | 33,27 % |
| EBITDA | -16,64 M | 22,38 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 11,49 M € |
Número de acciones | 236,35 M |
Máximo/mínimo de 52 semanas | 0,15 € - 0,031 € |
| Dividendos | No |
Beta | 2,13 |
Ratio P/E | -0,01 |
Ratio PEG | 0,00 |
Ratio P/B | 0,01 |
Ratio P/S | 128,14 |
Perfil de la empresa
Kazia Therapeutics Limited, una empresa de biotecnología centrada en oncología, desarrolla fármacos anticancerígenos. Su principal candidato en desarrollo es Paxalisib, una molécula pequeña e inhibidor con capacidad de penetración cerebral de la vía PI3K/Akt/mTor, que se desarrolla como posible terapia para el glioblastoma. También desarrolla EVT801, un fármaco en investigación para diversas formas de cáncer. La compañía era anteriormente conocida como Novogen Limited y cambió su nombre a Kazia Therapeutics Limited en noviembre de 2017. Kazia Therapeutics Limited se constituyó en 1994 y tiene su sede en Sídney, Australia.
| Nombre | Kazia Therapeutics |
| CEO | John E. Friend II, |
| Sede | Sydney,
nsw Australia |
| Sitio web | |
| Salida a bolsa | 30/09/1994 |
| Empleados | 12 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
Australian Securities Exchange Ltd | KZA.AX |
Frankfurt | NV9.F |